

Filed by Versum Materials, Inc.
pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-6
under the Securities Exchange Act of 1934
Subject Company: Versum Materials, Inc.
Commission File No.: 1-37664
Date: April 8, 2019


The following are select revised slides of an investor presentation previously filed by Versum Materials on April 1, 2019.

Announced Synergies Developed Through Comprehensive Review and Independently Assessed

Based on Detailed Analyses from Extensive Integration Planning by Both Companies alongside Leading Independent Management Consulting Firms

Updated Synergy Estimates			
	Description	Target	Timing
Cost	Administrative Functions	• Optimize costs (audit/consulting fees, IT hosting/app costs) and streamline functional organizations \$40mm	1 year post close
	Public Company Costs	• Optimize costs for board, executive leadership and associated administrative costs \$10mm	
	Business Operations	• Streamline organizational structure and optimize sales organization with lean/agile divisions, fully owning cost structure • Leverage combined capabilities and scale \$50mm	
	Manufacturing, Logistics and Procurement	• Harmonize supplier terms for like materials and consolidate suppliers to leverage scale (manufacturing, procurement, logistics) \$25mm	
Revenue	• Cross-selling across major customers and geographies • Co-optimized products • Integrated solutions \$50mm (run-rate EBITDA impact)	3 years post close	
CapEx	• Optimize manufacturing and laboratory expansions • Improve fleet management		
Tax	• Benefits from Entegris's more efficient tax structure		


Announced Cost Synergies as a % of Sales in Selected Transactions of Highly Complementary Businesses



(1) Based on realized synergies of \$35 million and sales of \$374 million; (2) Based on run-rate cost synergies of \$125 million.

Track Record of Creating Value via M&A Execution and Integration

Combined Company Has a Strong M&A Track Record



Integration Process is Well Underway

Rigorous planning process underway for integration

The integration teams of both companies **continue to evaluate** opportunities for savings

Engaged **leading independent management consulting firms** in February following the announcement of the merger to confirm and identify synergy opportunities

(1) Publicly announced \$30 million of synergies and achieved more than \$35 million; organic EBITDA CAGR of ~12.5% between 2014 and 2018; (2) Results ahead of management plan at time of acquisition; (3) Results ahead of management plan at time of acquisition; (4) TSR of 126% since spin-off (between September 2016 and April 2019); (5) Achieved synergies ahead of management plan at time of acquisition; (6) Results ahead of management plan at time of acquisition and expected synergies of ~5.5% of target sales.

Board Decision-Making Process was Characterized by Detailed Review, Extensive Diligence and Focused Planning

Comprehensive Process

- Since Versum's spin-off, the Board has consistently and rigorously evaluated various value-enhancing opportunities
 - Many discussions included possibility of combination with Entegris
- Involvement of leading legal and financial advisors throughout the process
- Ultimately determined merger of equals with Entegris to be the most compelling strategic transaction

Thorough Board Oversight

- Consistent Board involvement throughout the process
 - 5 meetings in January to discuss merger of equals with Entegris
 - 7 meetings since February 27 to assess Merck's offer and re-evaluate value creation from combination with Entegris
- Board has engaged in numerous discussions with shareholders in addition to hiring a second financial advisor to provide independent advice

Extensive Diligence

- Extensive operational, financial, legal, HR R&D and other diligence conducted through the process
- Detailed review and analysis of integration plans and synergies by combined Versum and Entegris teams
- Engaged leading independent management consulting firms in February following the announcement of the merger to confirm and identify synergy opportunities

Board Authorized Versum Management and Advisors to Engage in Further Discussions with Merck